|
🐜
|
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
24 auth.
J. Haschka,
M. Englbrecht,
A. Hueber,
B. Manger,
A. Kleyer,
M. Reiser,
S. Finzel,
H. Tony,
S. Kleinert,
M. Feuchtenberger,
...
M. Fleck,
K. Manger,
W. Ochs,
M. Schmitt-Haendle,
J. Wendler,
F. Schuch,
M. Ronneberger,
H. Lorenz,
H. Nuesslein,
R. Alten,
W. Demary,
J. Henes,
G. Schett,
J. Rech
|
7 |
2015 |
7
🐜
|
|
🐜
|
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
21 auth.
D. Simon,
Koray Tascilar,
F. Fagni,
G. Krönke,
A. Kleyer,
C. Meder,
R. Atreya,
M. Leppkes,
A. Kremer,
A. Ramming,
...
M. Pachowsky,
F. Schuch,
M. Ronneberger,
S. Kleinert,
A. Hueber,
K. Manger,
B. Manger,
C. Berking,
M. Sticherling,
M. Neurath,
G. Schett
|
7 |
2021 |
7
🐜
|
|
🐜
|
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment
26 auth.
J. Rech,
A. Hueber,
S. Finzel,
M. Englbrecht,
J. Haschka,
B. Manger,
A. Kleyer,
M. Reiser,
J. Cobra,
C. Figueiredo,
H. Tony,
S. Kleinert,
J. Wendler,
F. Schuch,
M. Ronneberger,
...
M. Feuchtenberger,
M. Fleck,
K. Manger,
W. Ochs,
M. Schmitt-Haendle,
H. Lorenz,
H. Nuesslein,
R. Alten,
J. Henes,
K. Krueger,
G. Schett
|
6 |
2015 |
6
🐜
|
|
🐜
|
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
31 auth.
D. Simon,
Koray Tascilar,
G. Krönke,
A. Kleyer,
M. Zaiss,
F. Heppt,
C. Meder,
R. Atreya,
E. Klenske,
P. Dietrich,
Abdullah Abdullah,
T. Kliem,
G. Corte,
H. Morf,
M. Leppkes,
...
A. Kremer,
A. Ramming,
M. Pachowsky,
F. Schuch,
M. Ronneberger,
S. Kleinert,
C. Maier,
A. Hueber,
K. Manger,
B. Manger,
C. Berking,
M. Tenbusch,
K. Überla,
M. Sticherling,
M. Neurath,
G. Schett
|
6 |
2020 |
6
🐜
|
|
🐜
|
Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade
8 auth.
J. Rech,
M. Ronneberger,
M. Englbrecht,
S. Finzel,
Julia Katzenbeisser,
K. Manger,
...
B. Manger,
G. Schett
|
5 |
2010 |
5
🐜
|
|
🐜
|
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs
27 auth.
C. Figueiredo,
H. Bang,
J. Cobra,
M. Englbrecht,
A. Hueber,
J. Haschka,
B. Manger,
A. Kleyer,
M. Reiser,
S. Finzel,
H. Tony,
S. Kleinert,
J. Wendler,
F. Schuch,
M. Ronneberger,
...
M. Feuchtenberger,
M. Fleck,
K. Manger,
W. Ochs,
M. Schmitt-Haendle,
H. Lorenz,
H. Nuesslein,
R. Alten,
J. Henes,
K. Krueger,
J. Rech,
G. Schett
|
5 |
2016 |
5
🐜
|
|
🐢
|
Standardization of Joint Examination Technique Leads to a Significant Decrease in Variability Among Different Examiners
8 auth.
M. Grunke,
C. Antoni,
A. Kavanaugh,
Verena Hildebrand,
C. Dechant,
G. Schett,
...
B. Manger,
M. Ronneberger
|
5 |
2010 |
5
🐢
|
|
🐜
|
Brief Report: Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in B cell depleted autoimmune patients.
19 auth.
D. Simon,
K. Tascilar,
K. Schmidt,
B. Manger,
Leonie Weckwerth,
M. Sokolova,
L. Bucci,
F. Fagni,
K. Manger,
F. Schuch,
...
M. Ronneberger,
A. Hueber,
U. Steffen,
D. Mielenz,
M. Herrmann,
T. Harrer,
A. Kleyer,
G. Krönke,
G. Schett
|
5 |
2021 |
5
🐜
|
|
🦁
|
Pathophysiology of Spondyloarthritis
M. Ronneberger,
G. Schett
|
5 |
2011 |
5
🦁
|
